Population‐based platelet reference values for an Iranian population

Adibi, Payman; Imani, Elham; Talaei, Mohammad; Ghanei, Masoud

doi:10.1111/j.1751-553x.2006.00843.x

Cited by 31 publications

(19 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…8,10-12 PDW is used to determine the heterogeneity of platelet size. 13,14 Platelet activation can cause both morphologic and quantitative changes of platelets. PC measures the number of platelets in the blood, and PCT is a complementary analysis of PC and measures the percentage of platelets in the blood.…”

Section: Introductionmentioning

confidence: 99%

The Role of Circulating Platelets Microparticles and Platelet Parameters in Acute Ischemic Stroke Patients

Chen

Xiao

Lin

et al. 2015

Journal of Stroke and Cerebrovascular Diseases

View full text Add to dashboard Cite

Background Platelet activation and aggregation are critical in the pathogenesis of acute ischemic stroke (AIS). Circulating platelet microparticles (PMPs) and platelet parameters are biological markers of platelet function in AIS patients, however, their associations with stroke subtypes and infarct volume remain unknown. Methods We recruited 112 AIS patients including large artery atherosclerosis (LAA) and small artery occlusion (SAO) subtypes, and 35 controls in this study. Blood samples were collected at admission and after antiplatelet therapy. The levels of circulating PMPs and platelet parameters [mean platelet volume (MPV), platelet count (PC), plateletocrit (PCT) and platelet distribution width (PDW)] were determined by flow cytometry and hematology analysis, respectively. Infarct volume was examined at admission by magnetic resonance imaging. Results (1) The levels of circulating PMPs and MPV were significantly elevated in AIS patients when compared with healthy controls; (2) The level of circulating PMPs, but not platelet parameters, was decreased after antiplatelet therapy in AIS patients; (3) The infarct volume in LAA subtype was larger than that in SAO subtype. Notably, circulating PMP level was positively correlated with the infarct volume in LAA subtype. No association with infarct volume in either AIS subtype was observed for platelet parameters; (4) According to the regression analysis, circulating PMPs was an independent risk factor for the infarct volume in pooled AIS patients after adjustments of other impact factors (hypertension and diabetes). Conclusions Our results suggest that circulating PMP level is associated with cerebral injury of AIS, which offers a novel evaluation parameter for AIS patients.

show abstract

Section: Introductionmentioning

confidence: 99%

The Role of Circulating Platelets Microparticles and Platelet Parameters in Acute Ischemic Stroke Patients

Chen

Xiao

Lin

et al. 2015

Journal of Stroke and Cerebrovascular Diseases

View full text Add to dashboard Cite

show abstract

“…19 Moreover, in some non-Western populations, platelet count values between 100 and 150 ϫ 10 9 /L are frequently found in apparently healthy people. [20][21][22] The new cutoff level will also avoid inclusion of most women with pregnancy-related thrombocytopenia, a well known physiologic phenomenon not requiring specific follow-up in the absence of additional clinical features 23 (Table 1).…”

Section: Recommendationsmentioning

confidence: 99%

Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group

Rodeghiero

Stasi

Gernsheimer

et al. 2009

Blood

2,285

2,277

View full text Add to dashboard Cite

Diagnosis and management of immune thrombocytopenic purpura (ITP) remain largely dependent on clinical expertise and observations more than on evidence derived from clinical trials of high scientific quality. One major obstacle to the implementation of such studies and in producing reliable meta-analyses of existing data is a lack of consensus on standardized critical definitions, outcome criteria, and terminology. Moreover, the demand for comparative clinical trials has dramatically increased since the introduction of new classes of therapeutic agents, such as thrombopoietin receptor agonists, and innovative treatment modalities, such as anti-CD 20 antibodies. To overcome the present heterogeneity, an International Working Group of recognized expert clinicians convened a 2-day structured meeting (the Vicenza Consensus Conference) to define standard terminology and definitions for primary ITP and its different phases and criteria for the grading of severity, and clinically meaningful outcomes and response.These consensus criteria and definitions could be used by investigational clinical trials or cohort studies. Adoption of these recommendations would serve to improve communication among investigators, to enhance comparability among clinical trials, to facilitate meta-analyses and development of therapeutic guidelines, and to provide a standardized framework for regulatory agencies. (Blood.

show abstract

“…In healthy non-western populations platelet count values between 100 and 150 Â 10 9 /L are frequent. 3,4 In addition, a prospective cohort study of healthy subjects with platelet count between 100 and 150 Â 10 9 /L showed only a 6.9% 10-year probability of developing a more severe thrombocytopenia. 5 The consensus group recommended a platelet count of less than 100 Â 10 9 /L to support a diagnosis of ITP.…”

Section: Definitionmentioning

confidence: 99%

Immune thrombocytopenia and pregnancy

Sankaran

Robinson

2011

Obstet Med

View full text Add to dashboard Cite

Summary: Immune thrombocytopenia (ITP) is not infrequently encountered during reproductive years with an estimated incidence of 0.1 -1 per 1000 pregnancies. An international consensus group recently re-defined ITP and outlined standardized response criteria and up-to-date investigation and management. The pathogenesis encompasses autoantibody platelet destruction and immunemediated decreased platelet production. Maternal antibodies may cross the placenta and have the potential to cause fetal and/or neonatal thrombocytopenia. The diagnosis and subsequent management of ITP in pregnancy requires a multidisciplinary approach involving the midwife, obstetrician, haematologist and anaesthetist. Women with ITP diagnosed prior to pregnancy should receive preconception counselling to outline potential treatments and provide information regarding expected maternal and neonatal outcome. Management prior to 36 weeks aims to avoid treatment in the absence of bleeding and ensure an acceptable platelet count for planned procedures. At 34-36 weeks, women are generally reviewed to consider whether a tailored course of treatment is required in preparation for delivery. Further research is required to determine a suitable platelet count for neuraxial anaesthesia. The mode of delivery should be guided by obstetric indication. It is pertinent to consider both the risk of maternal bleeding and thrombosis in maternal ITP. The risk of neonatal intracranial haemorrhage in association with ITP is less than 1%. Postpartum a cord blood platelet count should be checked. Additional management is dependent upon the neonatal platelet count. Data collection using the new standardized terminology should provide robust comparable epidemiological data regarding ITP in pregnancy.

show abstract

Population‐based platelet reference values for an Iranian population

Cited by 31 publications

References 14 publications

The Role of Circulating Platelets Microparticles and Platelet Parameters in Acute Ischemic Stroke Patients

The Role of Circulating Platelets Microparticles and Platelet Parameters in Acute Ischemic Stroke Patients

Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group

Immune thrombocytopenia and pregnancy

Contact Info

Product

Resources

About